HK1208363A1 - New methods - Google Patents

New methods

Info

Publication number
HK1208363A1
HK1208363A1 HK15109093.0A HK15109093A HK1208363A1 HK 1208363 A1 HK1208363 A1 HK 1208363A1 HK 15109093 A HK15109093 A HK 15109093A HK 1208363 A1 HK1208363 A1 HK 1208363A1
Authority
HK
Hong Kong
Prior art keywords
new methods
new
methods
Prior art date
Application number
HK15109093.0A
Other languages
English (en)
Chinese (zh)
Inventor
Marc F Pelletier
George William Farr
Paul Robert Mcguirk
Christopher H Hall
Walter F Boron
Original Assignee
Aeromics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromics Llc filed Critical Aeromics Llc
Publication of HK1208363A1 publication Critical patent/HK1208363A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15109093.0A 2012-05-08 2015-09-17 New methods HK1208363A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261644268P 2012-05-08 2012-05-08
US201261651778P 2012-05-25 2012-05-25
US201361799606P 2013-03-15 2013-03-15
PCT/US2013/040194 WO2013169939A2 (en) 2012-05-08 2013-05-08 New methods

Publications (1)

Publication Number Publication Date
HK1208363A1 true HK1208363A1 (en) 2016-03-04

Family

ID=49551452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109093.0A HK1208363A1 (en) 2012-05-08 2015-09-17 New methods

Country Status (14)

Country Link
US (4) US9994514B2 (xx)
EP (1) EP2846787B1 (xx)
JP (2) JP6238969B2 (xx)
KR (1) KR102200176B1 (xx)
CN (2) CN104602682B (xx)
AU (2) AU2013259526B2 (xx)
BR (1) BR112014027983B1 (xx)
CA (1) CA2872012C (xx)
ES (1) ES2699646T3 (xx)
HK (1) HK1208363A1 (xx)
IL (1) IL235512B (xx)
MX (1) MX363473B (xx)
RU (1) RU2671495C2 (xx)
WO (1) WO2013169939A2 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
US20180042873A1 (en) * 2014-11-13 2018-02-15 Aeromics, Inc. Novel methods
JP2018500388A (ja) * 2014-11-18 2018-01-11 ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー
CZ305738B6 (cs) * 2014-12-16 2016-02-24 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný derivát kyslíkatých kyselin fosforu, jeho použití a farmaceutický přípravek ho obsahující
US10246733B2 (en) 2015-06-04 2019-04-02 Case Western University Assay and method for quantitating carbonic anhydrase activity and assessing red blood hemolysis
CN105030747B (zh) * 2015-07-03 2017-11-17 厦门大学 氯硝柳胺在制备防治近视药物中的应用
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
RU2018144043A (ru) * 2016-05-13 2020-06-15 Аэромикс, Инк. Кристаллы
WO2017201313A1 (en) 2016-05-18 2017-11-23 Shengkan Jin Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
WO2018053807A1 (zh) * 2016-09-23 2018-03-29 深圳市中医院 氯硝柳胺乙醇胺盐在制备1型糖尿病药物中的应用
TWI631944B (zh) * 2016-10-14 2018-08-11 長庚大學 氯硝柳胺及其衍生物的用途
EP3624885A4 (en) 2017-05-19 2021-03-10 Trudell Medical International POSITIVE EXPIRATORY PRESSURE DEVICE
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
US10945995B2 (en) * 2017-09-26 2021-03-16 Deha, Llc Compositions and methods for channelopathy disorders-targeting fluid movement across membranes
CN108203719A (zh) * 2017-12-26 2018-06-26 吉林医药学院 用于治疗视神经脊髓炎的小分子化合物及其高通量筛选方法
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
USD902947S1 (en) * 2019-03-25 2020-11-24 Apple Inc. Electronic device with graphical user interface
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN117337182A (zh) * 2020-08-05 2024-01-02 江苏先声药业有限公司 一种水通道蛋白抑制剂的药物组合物及其制备方法
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE615511A (xx) 1961-03-25
NL292958A (xx) 1962-05-29 1900-01-01
GB8809205D0 (en) 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5137871A (en) * 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
DE4010536A1 (de) 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
US5137817A (en) 1990-10-05 1992-08-11 Amoco Corporation Apparatus and method for electroporation
DE4113820A1 (de) 1991-04-27 1992-10-29 Boehringer Mannheim Gmbh Verwendung von torasemid zur behandlung von hirnoedemen
US5486530A (en) 1991-04-27 1996-01-23 Boehringer Mannheim Gmbh Use of torasemide for the treatment of brain oedemas
US5858702A (en) 1991-12-13 1999-01-12 The Johns Hopkins University Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5)
US5741671A (en) 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US20060167110A1 (en) * 1995-01-13 2006-07-27 Blume Cherly D Methods for treating cerebrovascular disease by administering desmethylselegiline
WO1998021951A1 (en) 1996-11-18 1998-05-28 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
WO1999007382A1 (en) 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
US5905090A (en) * 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6500809B1 (en) * 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
ES2211460T3 (es) * 1999-12-10 2004-07-16 Pfizer Inc. Compuestos de 1,4-dihidropiridina sustituidos con un heteroalrilo de 5 miembros como antagonistas de la bradiquinina.
UA82827C2 (en) * 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
AU2003222020B2 (en) 2002-03-20 2008-08-28 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
JPWO2003103648A1 (ja) 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 糖尿病治療薬
CN1658854A (zh) 2002-06-05 2005-08-24 株式会社医药分子设计研究所 免疫关联蛋白激酶抑制剂
CA2487891A1 (en) 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
JP4743382B2 (ja) 2002-06-06 2011-08-10 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
CA2488367A1 (en) 2002-06-06 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Antiallergic agents
US20060089395A1 (en) * 2002-06-10 2006-04-27 Susumu Muto Nf-kb activation inhibitors
CA2488974A1 (en) 2002-06-10 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of cancer
EA011707B1 (ru) 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
KR20050019739A (ko) * 2002-06-11 2005-03-03 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 신경변성질환 치료제
CN1681487A (zh) 2002-07-15 2005-10-12 美瑞德生物工程公司 化合物、组合物及其使用方法
WO2004068928A2 (en) 2003-02-06 2004-08-19 Uutech Limited Bradykinin b2 receptor antagonist peptide from amphibian skin
DE602004002585T2 (de) * 2003-05-01 2007-10-25 Innogene Kalbiotech Pte. Ltd. Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen
CN100406006C (zh) 2003-07-16 2008-07-30 株式会社医药分子设计研究所 皮肤色素沉着的治疗剂
CN1886393A (zh) 2003-10-08 2006-12-27 沃泰克斯药物股份有限公司 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
US8467876B2 (en) * 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
WO2005039556A1 (ja) 2003-10-29 2005-05-06 Institute Of Medicinal Molecular Design. Inc. 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
EP1691817A2 (en) 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
ATE486606T1 (de) 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
US7601745B2 (en) * 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
WO2006074127A2 (en) 2005-01-04 2006-07-13 Novartis Ag Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
WO2007084464A2 (en) 2006-01-17 2007-07-26 The University Of North Carolina At Chapel Hill Water channel blockers and methods of use thereof
JP4273235B2 (ja) 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
KR20090027227A (ko) 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
WO2007143689A2 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US20100056444A1 (en) 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
WO2008052190A2 (en) 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2008067196A2 (en) 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
US20080171719A1 (en) 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US20080214486A1 (en) 2006-11-28 2008-09-04 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
US20120183600A1 (en) 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
CA2675638C (en) * 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
US20100092469A1 (en) 2007-02-09 2010-04-15 Simard J Marc Antagonists of a non-selective cation channel in neural cells
EP2124539A2 (en) 2007-02-17 2009-12-02 President and Fellows of Harvard College Compositions and method for tissue preservation
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
EP2178531A4 (en) 2007-07-02 2012-01-11 Yu Ming METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
AU2008314979A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of PAI-1 production
US8277845B2 (en) 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
GB0724340D0 (en) 2007-12-13 2008-01-30 Univ Dundee Novel Therapeutic Agents
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
WO2009139925A1 (en) * 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
WO2010033560A2 (en) 2008-09-16 2010-03-25 University Of Maryland, Baltimore Sur1 inhibitors for therapy
WO2010048273A2 (en) 2008-10-21 2010-04-29 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
WO2010079406A1 (en) * 2009-01-12 2010-07-15 Purapharm International (Hk) Limited Compounds and uses thereof for treating inflammation and modulating immune responses
US20120039805A1 (en) * 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
RU2564900C2 (ru) * 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
CN109172363A (zh) 2010-07-19 2019-01-11 比根切萨彼公司 静脉内施用格列苯脲和其他药物的方法
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
EP2685972A4 (en) 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS USING RAR ALPHA SELECTIVE AGONISTS
EP2717883B1 (en) 2011-05-02 2017-03-22 Stichting VUmc Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg)
RU2461375C1 (ru) 2011-05-19 2012-09-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ комбинированного лечения больных местно-распространенным раком желудка
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
EP2844345B1 (en) 2012-05-04 2022-08-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Modulators of the relaxin receptor 1
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
WO2015037659A1 (ja) 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 水溶液製剤及びその製造方法
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
DK3080134T3 (en) 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS
US20180042873A1 (en) 2014-11-13 2018-02-15 Aeromics, Inc. Novel methods
ES2927482T3 (es) 2015-05-29 2022-11-07 Univ Maryland Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales
ES2940669T3 (es) 2015-10-07 2023-05-10 Biogen Chesapeake Llc Métodos de tratamiento de lesiones o afecciones relacionadas con edema del SNC
RU2018144043A (ru) 2016-05-13 2020-06-15 Аэромикс, Инк. Кристаллы
CN109689037B (zh) 2016-07-29 2022-09-13 生物切萨皮克有限责任公司 利用sur1-trpm4通道抑制剂的医学治疗方法
CN117337182A (zh) 2020-08-05 2024-01-02 江苏先声药业有限公司 一种水通道蛋白抑制剂的药物组合物及其制备方法

Also Published As

Publication number Publication date
AU2018203357A1 (en) 2018-05-31
EP2846787B1 (en) 2018-08-29
US20150342967A1 (en) 2015-12-03
CA2872012C (en) 2017-06-20
KR102200176B1 (ko) 2021-01-11
AU2018203357C1 (en) 2020-06-25
RU2014148984A (ru) 2016-06-27
BR112014027983B1 (pt) 2022-05-24
KR20150035566A (ko) 2015-04-06
JP2018016647A (ja) 2018-02-01
AU2018203357B2 (en) 2020-01-30
CN109512805B (zh) 2021-12-31
JP6238969B2 (ja) 2017-11-29
US11873266B2 (en) 2024-01-16
EP2846787A4 (en) 2015-11-11
BR112014027983A2 (pt) 2017-06-27
US9573885B2 (en) 2017-02-21
AU2013259526A1 (en) 2014-12-18
US20150133405A1 (en) 2015-05-14
ES2699646T3 (es) 2019-02-12
IL235512B (en) 2018-06-28
MX363473B (es) 2019-03-25
US11084778B2 (en) 2021-08-10
JP6570597B2 (ja) 2019-09-04
CN109512805A (zh) 2019-03-26
US20220081391A1 (en) 2022-03-17
CN104602682B (zh) 2018-12-14
CA2872012A1 (en) 2013-11-14
US20180334424A1 (en) 2018-11-22
IL235512A0 (en) 2015-01-29
WO2013169939A3 (en) 2014-02-13
US9994514B2 (en) 2018-06-12
AU2013259526B2 (en) 2018-02-15
EP2846787A2 (en) 2015-03-18
JP2015520151A (ja) 2015-07-16
CN104602682A (zh) 2015-05-06
RU2671495C2 (ru) 2018-11-01
MX2014013639A (es) 2015-08-20
WO2013169939A2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
HK1250690A1 (zh) 方法
HK1208363A1 (en) New methods
EP2836211A4 (en) NOVEL PROCEDURE
DK3327112T3 (en) Agse-deficient stamme
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB2507760B (en) Methods
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
GB201208874D0 (en) Methods
EP2920157A4 (en) DI MACRO CYCLEN
EP2873363A4 (en) DIOPSIMETER
GB201204280D0 (en) Methods
EP2834250A4 (de) Lithiumsilikate
GB201208756D0 (en) Methods
GB201220686D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201209689D0 (en) Methods
GB201208963D0 (en) Methods
GB201208875D0 (en) Methods
GB201207793D0 (en) Methods
AU345893S (en) Treehouse
GB201211957D0 (en) SqueezMe
GB201210111D0 (en) Giggsters